Drug
Bixalomer clinical trials
Also written ASP1585 and AMG223.
- studies test it
- 15
- open now
- 0
- in phase 3
- 5
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 5 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Astellas Pharma Inc (12) · Amgen (1) · Amgen Research (Munich) GmbH (1) · Ilypsa (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bixalomer is read from its arms, and is right about nine times in ten.
Testing it · 15
- Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaCompletedPhase 2Astellas Pharma IncNCT02753894Written as ASP1585
- Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With HyperphosphatemiaCompletedPhase 2AmgenNCT00530114Written as AMG 223
- A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 CapsulesCompletedPhase 1Astellas Pharma IncNCT02531204Written as ASP1585
- Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedPhase 3Astellas Pharma IncNCT01742611Written as ASP1585
- A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal DialysisCompletedPhase 3Astellas Pharma IncNCT01017276Written as ASP1585
- Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisCompletedPhase 3Astellas Pharma IncNCT00892749Written as ASP1585
- A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedPhase 3Astellas Pharma IncNCT01057407Written as ASP1585
- A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedPhase 3Astellas Pharma IncNCT01742585Written as ASP1585
- A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled DrugCompletedPhase 1Astellas Pharma IncNCT01124747Written as ASP1585
- A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)CompletedPhase 1Amgen Research (Munich) GmbHNCT00756860Written as AMG 223
- A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedPhase 2Astellas Pharma IncNCT00505037Written as ASP1585
- A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy VolunteersCompletedPhase 1Astellas Pharma IncNCT01115972Written as ASP1585
- A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy VolunteersCompletedPhase 1Astellas Pharma IncNCT01115946Written as ASP1585
- A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy VolunteersCompletedPhase 1Astellas Pharma IncNCT01115985Written as ASP1585
- Efficacy and Tolerability of ILY101 in Dialysis Patients With HyperphosphatemiaStatus unknownPhase 2IlypsaNCT00358046Written as ILY101
Codes
What other systems call bixalomer · ClinicalTrials.gg INT000037
- MeSH (NLM) C000589735bixalomerOne source NLM
- UNII (FDA) 3160WY51LVBIXALOMERConfirmed FDA, NLM
- NCI Thesaurus C166622BixalomerOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589735 | bixalomer | One source NLM |
| UNII (FDA) | 3160WY51LV | BIXALOMER | Confirmed FDA, NLM |
| NCI Thesaurus | C166622 | Bixalomer | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.